Nilanjan Ghosh, MD, PhD, on Real-World Efficacy of CAR T-Cell Therapies


The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed data from real-world experience studies.

“There were lower rates of CRS and ICANS than in ZUMA-2 and most side effects were grade 1. These real-world experiences are very helpful, because clinical trials use a selected population of patients. We're seeing similar responses and toxicities in the real-world setting as the clinical trials. I think it’s very encouraging data.”

Currently approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies include lisocabtagene maraleucel (Breyanzi), axicabtagene cliolecleucel (Yescarta), brexucabtagene autoleucel (Tecartus)and ciltacabtagene autoleucel (Carvykti). As more CAR T therapies come to market, clinicians are beginning to see the long-term impact of these treatments in the clinic.

Among these clinicians is Nilanjan Ghosh, MD, PhD, chief of the lymphoma division and oncologist at Levine Cancer Institute. Ghosh has first-hand experience with these CAR T therapies on the clinic side and has seen their impact in patients with hematologic malignancies such as lymphomas.

CGTLive spoke to Ghosh to learn more about the future trajectory of CAR T-cell therapies in lymphomas. He discussed recent data seen in real-world experience studies of CAR T-cell therapies.

Related Videos
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
© 2024 MJH Life Sciences

All rights reserved.